The favorable outcomes in GIST with primary KIT mutations in exon 9 treated with sunitinib are consistent with in-vitro data, demonstrating greater potency of sunitinib over imatinib against exon 9 mutant KIT, and similar potency of each drug against exon 11 mutant KIT [22]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.